JP2019528306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528306A5 JP2019528306A5 JP2019511610A JP2019511610A JP2019528306A5 JP 2019528306 A5 JP2019528306 A5 JP 2019528306A5 JP 2019511610 A JP2019511610 A JP 2019511610A JP 2019511610 A JP2019511610 A JP 2019511610A JP 2019528306 A5 JP2019528306 A5 JP 2019528306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- insulin
- group
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022122568A JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381263P | 2016-08-30 | 2016-08-30 | |
| US62/381,263 | 2016-08-30 | ||
| US201662411032P | 2016-10-21 | 2016-10-21 | |
| US62/411,032 | 2016-10-21 | ||
| PCT/US2017/049137 WO2018044903A1 (en) | 2016-08-30 | 2017-08-29 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122568A Division JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528306A JP2019528306A (ja) | 2019-10-10 |
| JP2019528306A5 true JP2019528306A5 (enExample) | 2020-10-08 |
| JP7173962B2 JP7173962B2 (ja) | 2022-11-16 |
Family
ID=59799505
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511610A Active JP7173962B2 (ja) | 2016-08-30 | 2017-08-29 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2022122568A Active JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A Pending JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022122568A Active JP7633213B2 (ja) | 2016-08-30 | 2022-08-01 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| JP2024159035A Pending JP2024178249A (ja) | 2016-08-30 | 2024-09-13 | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10995146B2 (enExample) |
| EP (1) | EP3506940A1 (enExample) |
| JP (3) | JP7173962B2 (enExample) |
| KR (3) | KR102708864B1 (enExample) |
| CN (2) | CN109922831A (enExample) |
| AU (2) | AU2017321423C1 (enExample) |
| CA (1) | CA3034777A1 (enExample) |
| IL (1) | IL322691A (enExample) |
| MA (1) | MA46089A (enExample) |
| MX (2) | MX385598B (enExample) |
| SG (2) | SG11201901355SA (enExample) |
| WO (1) | WO2018044903A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102708864B1 (ko) | 2016-08-30 | 2024-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 |
| CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| MX2021008797A (es) * | 2019-01-23 | 2022-01-31 | Regeneron Pharma | Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7). |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| US12398202B2 (en) | 2019-09-04 | 2025-08-26 | Apharma | Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance |
| CN113481290B (zh) * | 2021-06-30 | 2022-08-23 | 华南农业大学 | 一种klf4基因在制备检测和/或减少母鼠不良妊娠结局的产品中的应用 |
| CN114342875A (zh) * | 2022-01-12 | 2022-04-15 | 吉林大学 | 一种新型妊娠糖尿病动物模型的建立方法 |
| EP4708502A1 (en) | 2023-08-21 | 2026-03-11 | LG Energy Solution, Ltd. | Cell assembly, battery module including same, and method for manufacturing cell assembly |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836308B2 (ja) | 1977-02-10 | 1983-08-08 | 大塚製薬株式会社 | 抗体の製造方法 |
| US4206199A (en) | 1977-07-22 | 1980-06-03 | Takeda Chemical Industries, Ltd. | Novel glucagon fragment and its derivatives |
| JPS56163456A (en) | 1980-05-21 | 1981-12-16 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
| US4423034A (en) | 1980-10-16 | 1983-12-27 | Toyo Jozo Kabushiki Kaisha | Process for the preparation of antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE285472T1 (de) | 1992-08-28 | 2005-01-15 | Novo Nordisk As | Glucagonrezeptoren |
| JP2729159B2 (ja) | 1994-10-31 | 1998-03-18 | 日清製粉株式会社 | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7301036B2 (en) | 2003-12-19 | 2007-11-27 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| ATE395338T1 (de) | 2004-06-04 | 2008-05-15 | Merck & Co Inc | Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| JP2008505905A (ja) | 2004-07-07 | 2008-02-28 | メルク エンド カムパニー インコーポレーテッド | ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法 |
| EP1773330B1 (en) | 2004-07-22 | 2010-05-26 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| US8084489B2 (en) | 2005-02-11 | 2011-12-27 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| JP2008533200A (ja) | 2005-03-21 | 2008-08-21 | メルク エンド カムパニー インコーポレーテッド | 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法 |
| WO2006104826A2 (en) | 2005-03-30 | 2006-10-05 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| EP2015776A1 (en) | 2006-04-20 | 2009-01-21 | Amgen Inc. | Glp-1 compound/glucagon antibody compositions |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| PT2129654E (pt) | 2007-02-09 | 2014-09-04 | Metabasis Therapeutics Inc | Antagonistas do receptor de glucagina |
| CL2009000586A1 (es) | 2008-03-27 | 2010-06-04 | Lilly Co Eli | Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso |
| JP2011520897A (ja) | 2008-05-16 | 2011-07-21 | シェーリング コーポレイション | グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法 |
| EP2346830B1 (en) | 2008-09-15 | 2015-05-13 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010071750A1 (en) | 2008-12-19 | 2010-06-24 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
| US20110281795A1 (en) | 2009-01-28 | 2011-11-17 | Songnian Lin | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010093535A1 (en) | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8809579B2 (en) | 2009-02-13 | 2014-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩 |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| CA2849273C (en) | 2011-09-20 | 2020-07-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of gcgr expression |
| US9453073B2 (en) | 2011-12-02 | 2016-09-27 | Eli Lilly And Company | Anti-glucagon antibodies and uses thereof |
| WO2014181229A2 (en) | 2013-05-07 | 2014-11-13 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| MX2017003535A (es) * | 2014-09-16 | 2017-10-27 | Regeneron Pharma | Anticuerpos anti-glucagon y sus usos. |
| KR102708864B1 (ko) | 2016-08-30 | 2024-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 |
-
2017
- 2017-08-29 KR KR1020237014250A patent/KR102708864B1/ko active Active
- 2017-08-29 WO PCT/US2017/049137 patent/WO2018044903A1/en not_active Ceased
- 2017-08-29 SG SG11201901355SA patent/SG11201901355SA/en unknown
- 2017-08-29 US US16/328,935 patent/US10995146B2/en active Active
- 2017-08-29 IL IL322691A patent/IL322691A/en unknown
- 2017-08-29 CN CN201780065987.7A patent/CN109922831A/zh active Pending
- 2017-08-29 JP JP2019511610A patent/JP7173962B2/ja active Active
- 2017-08-29 AU AU2017321423A patent/AU2017321423C1/en active Active
- 2017-08-29 CN CN202410379157.3A patent/CN118236497A/zh active Pending
- 2017-08-29 CA CA3034777A patent/CA3034777A1/en active Pending
- 2017-08-29 MX MX2019002437A patent/MX385598B/es unknown
- 2017-08-29 EP EP17762315.4A patent/EP3506940A1/en active Pending
- 2017-08-29 SG SG10201913074WA patent/SG10201913074WA/en unknown
- 2017-08-29 MA MA046089A patent/MA46089A/fr unknown
- 2017-08-29 KR KR1020247021936A patent/KR20240110661A/ko not_active Ceased
- 2017-08-29 KR KR1020197008021A patent/KR20190044079A/ko not_active Ceased
-
2019
- 2019-02-28 MX MX2021006457A patent/MX2021006457A/es unknown
-
2021
- 2021-04-05 US US17/222,236 patent/US11708416B2/en active Active
-
2022
- 2022-08-01 JP JP2022122568A patent/JP7633213B2/ja active Active
-
2023
- 2023-06-05 US US18/329,358 patent/US20230416384A1/en active Pending
-
2024
- 2024-09-13 JP JP2024159035A patent/JP2024178249A/ja active Pending
- 2024-12-19 AU AU2024278594A patent/AU2024278594A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528306A5 (enExample) | ||
| JP7579227B2 (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2025176106A (ja) | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 | |
| AU2021250850B2 (en) | Dosage regimen for madcam antagonists | |
| Kotsovilis et al. | Therapeutic human monoclonal antibodies in inflammatory diseases | |
| JP2014533279A5 (enExample) | ||
| Fan et al. | The use of biological agents in the treatment of rheumatoid arthritis | |
| JP2019528285A5 (enExample) | ||
| CN115768466A (zh) | 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法 | |
| AU2017312049A1 (en) | Methods of treating Crohn's Disease with an anti-NKG2D antibody | |
| CN102307899A (zh) | 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂 | |
| JP2024069230A5 (enExample) | ||
| JP2021502065A5 (enExample) | ||
| CN102834413A (zh) | 代谢障碍的治疗 | |
| CN113166238B (zh) | 使用抗体及其片段对免疫检测点抑制剂诱导的腹泻、结肠炎或小肠结肠炎的局部治疗 | |
| TW202235435A (zh) | 抗cd38抗體及其用途 | |
| JP2022548004A (ja) | オマリズマブを使用した治療方法 | |
| JP2020517648A5 (enExample) | ||
| TW202112373A (zh) | 使用抗cd38抗體之組合療法 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| RU2019107807A (ru) | Способы лечения тяжелой инсулинорезистентности путем прерывания передачи сигнала глюкагонового рецептора | |
| JPWO2022032135A5 (enExample) | ||
| RU2022112615A (ru) | Способы лечения тяжелой инсулинорезистентности путем прерывания предачи сигнала глюкагонового рецептора |